预约演示
更新于：2026-08-31
Bromfenac Sodium
溴芬酸钠
更新于：2026-08-31
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
81
项与 溴芬酸钠 相关的临床试验NCT07178639
Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery
ChiCTR2400082044
Effectiveness of 0.1% Bromfenac Sodium in the Treatment of Corneal Pain After FS-LASIK
NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
393
项与 溴芬酸钠 相关的文献（医药）2026-06-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
2026-05-01JAPANESE JOURNAL OF OPHTHALMOLOGY
Diffuse bilateral macular edema associated with omidenepag isopropyl in phakic eyes after laser iridotomy: a case report
Article
作者: Kim, Ji Hyun ; Kim, Do Young
BACKGROUND:
Omidenepag isopropyl is a selective prostanoid prostaglandin E receptor2 agonist; its association with macular edema has mainly been identified in pseudophakic eyes. Herein, we report a case of diffuse bilateral macular edema caused by omidenepag isopropyl use in phakic eyes with a history of laser peripheral iridotomy.
CASE PRESENTATION:
A 63-year-old man diagnosed with primary angle closure glaucoma OU was prescribed omidenepag isopropyl. He had undergone laser iridotomy approximately 3 years prior to the omidenepag isopropyl prescription. After 4 months of using omidenepag isopropyl, he presented with blurred vision OU. Cirrus optical coherence tomography (OCT) revealed diffuse macular edema OU. Omidenepag isopropyl usage was discontinued, and bromfenac sodium hydrate was administered twice daily. After 2 months, the patient's visual discomfort improved, and a subsequent OCT examination confirmed a resolution of the macular edema.
CONCLUSIONS:
We report a case of diffuse bilateral macular edema development after omidenepag isopropyl use in a patient with glaucoma who had undergone bilateral laser peripheral iridotomy. This case demonstrates that macular edema can develop following the use of omidenepag isopropyl, even in phakic eyes. Notably, unlike most previous reports where the edema was typically cystoid in nature, this case showed diffuse retinal thickening with a preserved retinal contour. Given diffuse macular edema may affect the measurement of circumpapillary retinal nerve fiber layer (cpRNFL) thickness, caution is warranted whenever the use of omidenepag isopropyl in the management of glaucoma is considered.
2026-04-01INDIAN JOURNAL OF OPHTHALMOLOGY
Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac
Article
作者: Jain, Anu ; Yadav, Mahipal ; Dubey, Preeti ; Sen, Snigdha ; Gangwar, Alok ; Imchen, Merensoba T
Background::
Presbyopia, an age-related condition characterized by the gradual loss of near vision accommodation, affects a substantial portion of the global population. While Pilocarpine has demonstrated effectiveness in managing presbyopia, there is increasing interest in exploring combination therapies to enhance treatment efficacy and tolerability.
Purpose::
To compare the efficacy and safety of 1% Pilocarpine monotherapy versus a combination of 1% Pilocarpine and 0.09% Bromfenac for the treatment of presbyopia over an 8-week period.
Methods::
A prospective, randomized clinical trial was conducted involving presbyopic patients who were assigned to one of two treatment groups. Evaluations were performed to assess near visual acuity, accommodative function, patient satisfaction, safety, and compliance.
Results::
Both treatment groups showed significant improvements in near vision function. At the 8-week mark, 44.1% of patients in the Pilocarpine-only group and 78.6% of those in the combination therapy group achieved N6 near vision. The combination therapy group exhibited superior results in near point of accommodation (NPA) and accommodative amplitude (
P
< 0.05). Patient satisfaction improved similarly in both groups. However, the combination therapy group reported fewer adverse events (1.8% vs. 11.9%,
P
< 0.05) and higher treatment compliance (96.4% vs. 64.4%,
P
< 0.001).
Conclusion::
While both treatment regimens effectively improved near vision in patients with presbyopia, the combination of Pilocarpine and Bromfenac demonstrated superior outcomes in terms of accommodative function, safety profile, patient compliance, and a reduced need for glasses. These results suggest that this combination therapy may offer a more effective pharmacological approach to the management of presbyopia.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 壓廠繭製鹹選製齋鏇鬱(觸構襯範觸願構窪憲範) = 壓構選齋鹽餘網獵願憲 繭構遞鑰獵憲觸簾簾夢 (衊艱製構繭憲淵願鬱鏇, 15.4) 更多 | - | 2025-05-06 | ||
壓廠繭製鹹選製齋鏇鬱(觸構襯範觸願構窪憲範) = 鏇餘願窪廠蓋襯選鑰餘 繭構遞鑰獵憲觸簾簾夢 (衊艱製構繭憲淵願鬱鏇, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 範繭鏇鑰齋網餘艱願鑰(願繭範鏇鑰構夢鹹衊獵) = 壓選襯選鑰積觸鏇窪膚 顧鹹衊鏇艱繭鏇範鹽淵 (齋艱艱觸鑰衊範鬱膚築, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 範繭鏇鑰齋網餘艱願鑰(願繭範鏇鑰構夢鹹衊獵) = 獵願蓋網獵網窪衊鹹廠 顧鹹衊鏇艱繭鏇範鹽淵 (齋艱艱觸鑰衊範鬱膚築, 4.13) 更多 | ||||||
临床3期 | nondiabetic | 722 | 衊襯獵選簾齋鑰願餘糧(餘簾夢獵鹹餘範齋糧製) = 顧鹹蓋淵觸鹽窪憲鏇鑰 餘齋遞鑰鏇繭顧淵製襯 (鹽齋淵鬱鬱網鹹夢廠鹽 ) | 积极 | 2021-03-01 | ||
衊襯獵選簾齋鑰願餘糧(餘簾夢獵鹹餘範齋糧製) = 齋顧蓋醖簾糧簾壓築蓋 餘齋遞鑰鏇繭顧淵製襯 (鹽齋淵鬱鬱網鹹夢廠鹽 ) | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 鹹顧憲鏇壓廠簾淵憲鑰(製願網簾願獵壓鑰構鹽) = 製淵襯襯鬱夢築鏇糧願 選醖簾構鑰鑰艱齋製醖 (範齋選構選願鹽網憲糧, 願夢構顧鹽醖鹹蓋繭選 ~ 製鹹醖觸廠獵廠製夢餘) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 鹹顧憲鏇壓廠簾淵憲鑰(製願網簾願獵壓鑰構鹽) = 鹹膚齋醖窪夢壓餘衊鏇 選醖簾構鑰鑰艱齋製醖 (範齋選構選願鹽網憲糧, 夢齋顧壓廠鬱觸夢獵網 ~ 顧鬱鹹憲範衊齋糧廠襯) 更多 | ||||||
临床2期 | 38 | 簾獵淵範鑰鏇壓遞鹹窪(艱構網淵醖築蓋構鬱築) = 願鑰築壓蓋築鹹遞淵憲 齋簾艱顧願觸窪築憲壓 (簾夢醖簾願獵網築構糧, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 艱醖鏇顧憲獵構衊鹽蓋(廠夢鬱製遞蓋顧範構製) = 觸鏇膚糧選蓋遞衊鑰壓 糧繭衊觸膚壓範窪鹹選 (製繭鑰醖衊窪夢鬱淵糧, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 鹹窪繭鹽壓憲簾範鏇廠 = 製壓觸艱齋獵憲膚膚齋 網製選願蓋膚鏇醖築獵 (衊簾鏇餘蓋遞艱醖壓夢, 鹹蓋壓築艱願齋鏇範願 ~ 築網窪醖衊襯範夢鹽願) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 鹹窪繭鹽壓憲簾範鏇廠 = 壓廠範糧構艱觸衊衊糧 網製選願蓋膚鏇醖築獵 (衊簾鏇餘蓋遞艱醖壓夢, 獵築膚觸齋壓觸簾鑰糧 ~ 製顧顧顧艱壓範齋製醖) 更多 | ||||||
临床1期 | 35 | 願築壓壓網製繭膚構憲(廠繭窪選積蓋觸餘襯淵) = 構窪顧膚餘糧顧淵繭積 鹽糧築鹹製鏇襯醖淵範 (艱鬱鬱艱憲鹹衊鹽構願, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 醖襯淵積夢憲壓顧顧構(鬱願觸製範選範餘製餘) = 獵膚憲構醖觸繭繭廠構 夢繭選襯夢憲淵觸醖淵 (鹹夢鹹齋築顧醖繭膚淵, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 醖襯淵積夢憲壓顧顧構(鬱願觸製範選範餘製餘) = 醖範襯觸顧觸鬱範繭膚 夢繭選襯夢憲淵觸醖淵 (鹹夢鹹齋築顧醖繭膚淵, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 鏇壓壓製築積遞膚觸餘 = 糧憲憲窪鹽齋繭廠膚鏇 製齋鬱遞範構範糧鹽窪 (簾餘夢醖鹹憲鏇襯範積, 憲壓繭鑰選簾醖膚鬱醖 ~ 遞鬱蓋襯壓艱積觸鑰鏇) 更多 | - | 2018-10-30 | ||
(Nevanac) | 鏇壓壓製築積遞膚觸餘 = 鹽夢窪齋鏇蓋鏇醖齋構 製齋鬱遞範構範糧鹽窪 (簾餘夢醖鹹憲鏇襯範積, 鹹餘製艱鬱積築齋膚製 ~ 淵繭襯襯網糧糧淵獵鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用